GSK gets EU go-ahead for triple therapy inhaler in COPD
November 16, 2017Sales and Marketing COPD, FDA, GSK, Trelegy Ellipta, pharma
The EMA has awarded EU marketing authorisation to GlaxoSmithKline and Innovia’s single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for …
NICE approves Novartis and Pfizer’s rival breast cancer drugs
November 16, 2017Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical
NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …
Genentech cements relationship with Arvinas with $650m deal
November 16, 2017Research and Development, Sales and Marketing Arvinas, Genentech, Roche, biotech, drugs, pharma, pharmaceutical
Genentech first signed a deal with Arvinas, a biotech focused on drugs within the protein degradation class, back in 2015. …
Navigating the new Clinical Trial Regulation with DIA
November 16, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dia, drugs, pharma, pharmaceutical
For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will …
Pfizer promotes Albert Bourla to newly-created COO role
November 15, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
In a sizeable shake-up of its business operations, Pfizer has promoted Albert Bourla (pictured) to the role of Chief Operating …
NHS backs innovative means of cutting diabetes risk
November 15, 2017Medical Communications, Research and Development NHS, biotech, drugs, pharma, pharmaceutical
It was World Diabetes Day yesterday and the NHS announced a new tech initiative to help those most at risk …
Promising new CAR-T therapy able to target T-cell lymphoma
November 15, 2017Research and Development Autolus, CAR T, CAR-T, biotech, drugs, pharma, pharmaceutical
The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to …
Psoriasis patients at greater risk of type 2 diabetes, study reveals
November 15, 2017Research and Development diabetes, pharma, psoriasis, type 2 diabetes
Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk …
FDA signals crackdown on controversial painkiller
November 15, 2017Medical Communications, Research and Development biotech, drugs, kratom, pharma, pharmaceutical
Scott Gottlieb, the FDA’s Commissioner, issued an advisory about the medicinal plant-product known as kratom. The plant is known to …
AstraZeneca’s Fasenra scores US approval in severe asthma
November 15, 2017Research and Development, Sales and Marketing AstraZeneca, Fasenra, MedImmune, asthma
AstraZeneca and MedImmune, the company’s biologics research and development division, have revealed the decision by the FDA to approve Fasenra …
WestRock’s Multi Packaging Solutions partners with Smartglyph for SmarterBarcodes
November 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Multi Packaging Solutions
Multi Packaging Solutions, (MPS), a business of WestRock Company and a leader in value-added print and packaging solutions for the …
Navigating the new Clinical Trial Regulation with DIA
November 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dia, drugs, pharma, pharmaceutical
For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will …
Boehringer celebrates EU approval of Humira biosimilar
November 14, 2017Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 14, 2017Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …
Pfizer creates COO role so CEO Ian Read can focus on deal-making
November 14, 2017Manufacturing and Production, Sales and Marketing Image Credit: Pfizer
In a sizeable shake-up of its business operations, Pfizer has promoted Albert Bourla (pictured) to the role of Chief Operating …
Ex-Lilly exec Trump’s nominee for health secretary
November 14, 2017Manufacturing and Production, Medical Communications Alex Azar, Donald Trump, biotech, drugs, pharma, pharmaceutical
Alex Azar is officially President Trump’s nominee for the position as head of the Health and Human Services (HHS) agency, …
Hansa Medical mourns death of CEO
November 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hansa Medical, pharma
Swedish biopharma firm Hansa Medical broke tragic and unexpected news in November when it announced the death of its CEO …
EMA Headquarters: There’s no place like home
November 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, biotech, brexit, drugs, pharma, pharmaceutical
With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …
Mylan to withdraw from Tel Aviv Stock Exchange
November 13, 2017Sales and Marketing Mylan, TASE, pharma
US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement …
Novartis touts longer-lasting AMD rival to Eylea
November 13, 2017Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical
Novartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
